首页> 外文OA文献 >Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody

【2h】

Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody

机译：非临床药代动力学，预测人类药代动力学和CNTO 5825的第一对人剂量选择，抗白细胞介素-13单克隆抗体

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ivo P. Nnane; Zhenhua Xu; Honghui Zhou; Hugh M. Davis;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody [J] . Nnane Ivo P., Xu Zhenhua, Zhou Honghui, Basic & clinical pharmacology & toxicology. . 2015,第4期

机译：抗白细胞介素13单克隆抗体CNTO 5825的非临床药代动力学，人类药代动力学预测和人选剂量选择。
2. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study [J] . VanHartingsveldtB., NnaneI.P., Bouman-ThioE., British Journal of Clinical Pharmacology . 2013,第5期

机译：人类抗白细胞介素13单克隆抗体（CNTO 5825）的安全性，耐受性和药代动力学
3. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study [J] . Bart van Hartingsveldt, Ivo P. Nnane, Esther Bouman-Thio, British journal of clinical pharmacology . 2013,第5期

机译：人类抗白介素13单克隆抗体（CNTO 5825）的安全性，耐受性和药代动力学
4. Pharmacokinetic Modeling For Evaluating Dosing Strategies Of Anti P 185/supHER2/ Monoclonal Antibodies [C] . Schoenhoff, M., Maneval, . 2001

机译：评估抗P 185 / supHER2 /单克隆抗体给药策略的药代动力学模型
5. Integration of preclinical and clinical data with pharmacokinetic modeling and simulations to characterize the disposition of orally-active antiparasitic prodrugs and metabolites: Prediction of the dose-exposure relationship in humans. [D] . Yan, Zhixia. 2011

机译：临床前和临床数据与药代动力学建模和模拟的集成，以表征口服活性抗寄生虫前药和代谢物的分布：预测人类的剂量-暴露关系。
6. Safety tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study [O] . Bart Hartingsveldt, Ivo P Nnane, Esther Bouman-Thio, 2013

机译：人类抗白细胞介素13单克隆抗体（CNTO 5825）的安全性耐受性和药代动力学
7. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial. [O] . Vincent Meininger, Pierre-François Pradat, Andrea Corse, 2014

机译：nogo-a单克隆抗体在肌萎缩侧索硬化症中的安全性，药代动力学和功能效应：一项随机，首次人体临床试验。

Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody

著录项

引文网络

相似文献

相关主题

期刊订阅